Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its business expansion plans and restructuring ...

Nevro Corp. NVRO reported a loss per share of 64 cents in the fourth quarter of 2024, wider than the year-ago quarter’s loss ...

Nevro Corp. (NYSE:NVRO – Get Free Report) has earned a consensus rating of “Reduce” from the thirteen research firms that are ...

As previously announced on February 6, given the pending acquisition of Nevro (NVRO) by Globus Medical, Nevro is not issuing FY25 guidance, nor ...

Globus Medical currently awaits a strong cadence of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.

Analysts at StockNews.com initiated coverage on shares of Nevro (NYSE:NVRO – Get Free Report) in a research note issued on ...

Reports Q4 revenue $105.5M, consensus $102.61M. Cash, cash equivalents and short-term investments totaled $292.5M as of December 31, 2024, an ...

Management uses certain non-GAAP financial measures, most specifically adjusted EBITDA, as a supplement to GAAP financial measures to further evaluate the Company's operating performance period ...

The Redwood City, California-based company said it had a loss of $1.41 per share. Losses, adjusted for one-time gains and costs, came to 64 cents per share. The results surpassed Wall Street ...

Nevro Corp. NVRO reported a loss per share of 64 cents in the fourth quarter of 2024, wider than the year-ago quarter’s loss of 15 cents. The Zacks Consensus Estimate is pegged at a loss per ...

U.S. revenue in the fourth quarter of 2024 was $91.4 million, a decrease of 9.9% compared with $101.5 million in the prior year period. U.S. permanent implant procedures decreased by 7.0% compared ...

REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic ...